CTLT Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 0.31%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,164,871.56

Catalent Insider Trading History Chart

This chart shows the insider buying and selling history at Catalent by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Catalent Share Price & Price History

Current Price: $63.48
Price Change: +0.30 (1.20%)
As of 12/18/2024 01:00 AM ET

This chart shows the closing price history over time for CTLT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for Catalent (NYSE:CTLT)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CTLT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$629kbought$385MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1B$0$1BTotal InflowsTotal Outflows
Catalent logo
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
Read More on Catalent

Today's Range

Now: $63.48
Low: $63.48
High: $63.48

50 Day Range

MA: $62.87
Low: $59.66
High: $63.48

52 Week Range

Now: $63.48
Low: $53.51
High: $63.50

Volume

N/A

Average Volume

1,911,113 shs

Market Capitalization

$11.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Who are the company insiders with the largest holdings of Catalent?

Catalent's top insider investors include:
  1. Alessandro Maselli (CEO)
  2. Aristippos Gennadios (Insider)
  3. Steven L Fasman (EVP)
  4. Scott Gunther (SVP)
  5. David Mcerlane (Insider)
  6. John J Greisch (Insider)
  7. Matti Masanovich (CFO)
  8. Ricky Hopson (Insider)
  9. Joseph Anthony Ferraro (SVP)
  10. Ricardo Pravda (Insider)
  11. Manja Boerman (Insider)
  12. Michelle R Ryan (Director)
  13. Mario Gargiulo (SVP)
  14. Charles Lickfold (SVP)
Learn More about top insider investors at Catalent.

Who are the major institutional investors of Catalent?

Catalent's top institutional investors include:
  1. Barclays PLC — 0.06%
  2. Resona Asset Management Co. Ltd. — 0.01%
  3. Blue Trust Inc. — 0.00%
  4. Blue Trust Inc. — 0.00%
  5. FNY Investment Advisers LLC — 0.00%
  6. Walleye Trading LLC — 0.00%
Learn More about top institutional investors of Catalent stock.

Which institutional investors are selling Catalent stock?

In the previous quarter, CTLT stock was sold by these institutional investors:
  1. Barclays PLC
  2. Caption Management LLC
  3. LMR Partners LLP
  4. Maven Securities LTD
  5. Schonfeld Strategic Advisors LLC
  6. Squarepoint Ops LLC
  7. Nomura Holdings Inc.
  8. Jane Street Group LLC
Within the last year, company insiders that have sold Catalent company stock include:
  1. Alessandro Maselli (CEO)
  2. Aristippos Gennadios (Insider)
  3. Steven L Fasman (EVP)
  4. Scott Gunther (SVP)
  5. David Mcerlane (Insider)
  6. John J Greisch (Insider)
  7. Matti Masanovich (CFO)
Learn More investors selling Catalent stock.

Which institutional investors are buying Catalent stock?

During the previous quarter, CTLT stock was bought by institutional investors including:
  1. Resona Asset Management Co. Ltd.
  2. Blue Trust Inc.
  3. Blue Trust Inc.
  4. FNY Investment Advisers LLC
During the previous year, these company insiders have bought Catalent stock:
  1. Alessandro Maselli (CEO)
  2. Aristippos Gennadios (Insider)
Learn More investors buying Catalent stock.